WINNIPEG, MB, June 25, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.
This program offers many advantages to Medicure to facilitate an increase in patient access to ZYPITAMAGTM for patients who hold a prescription, which includes direct shipment of the product to a patient's home at no cost, the processing of prior authorizations, and direct to patient refill reminders. Ultimately, marketing and distribution of ZYPITAMAGTM through this program will provide reduced costs to the patient, including no retail pharmacy filling fees, and increase the availability of the product to consumers. It also provides a seamless process for physicians and prescribers, and reduces their workload by processing any prior authorization.
"We are excited to kickoff this online program to increase patient access to ZYPITAMAGTM across the United States and reduce one of the impediments to the growth of the product" commented Medicure's CEO, Dr. Albert D. Friesen. "We look forward to growing the ZYPITAMAGTM brand as part of our portfolio of cardiovascular products."
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS PRO™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. For additional information about ZYPITAMAGTM, refer to the full Prescribing Information.